Alnylam (ALNY) Targets 25% CAGR with Innovative Therapies [Yahoo! Finance]
Alnylam Pharmaceuticals, Inc. (ALNY)
Last alnylam pharmaceuticals, inc. earnings: 2/6 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.alnylam.com/investor-overview
Company Research
Source: Yahoo! Finance
its growth strategy at the TD Cowen 46th Annual Health Care Conference, emphasizing significant revenue expansion and ongoing innovation in RNAi therapies. The company expects revenue of around $4.4 billion to $4.7 billion by 2026, indicating strong growth and a 25% CAGR through 2030. It also aims for 30% operating margins, which might rise to the mid-40% levels after future product releases. A significant aim is to reinvest 30% of sales in R&D to accelerate pipeline advancement. With more than 90% first-line patient access, AMVUTTRA continues to be a significant growth driver as Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) gets primed for competition from WAINUA. The company is also advancing its pipeline, which includes the TRITON research, alongside plans to broaden into 10 tissues by 2030. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is a prominent biopharmaceutical company focused on RNA interference (RNAi) treatments, with a number of FDA-approved medications for rare geneti
Show less
Read more
Impact Snapshot
Event Time:
ALNY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALNY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALNY alerts
High impacting Alnylam Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
ALNY
News
- Alnylam Pharmaceuticals (ALNY) had its "buy" rating reaffirmed by Chardan Capital. They now have a $425.00 price target on the stock.MarketBeat
- Alnylam Pharmaceuticals (ALNY) had its "buy" rating reaffirmed by HC Wainwright. They now have a $510.00 price target on the stock.MarketBeat
- Alnylam Pharmaceuticals, Inc. (ALNY) Discusses Progress and Strategy in Transforming ATTR Amyloidosis Care and Expanding TTR Franchise Transcript [Seeking Alpha]Seeking Alpha
- Alnylam Advances Future of ATTR-CM Care Through Strategic Collaboration with Viz.ai and Support for the American Heart Association [Yahoo! Finance]Yahoo! Finance
- Alnylam Advances Future of ATTR-CM Care Through Strategic Collaboration with Viz.ai and Support for the American Heart AssociationBusiness Wire
ALNY
Earnings
- 2/12/26 - Beat
ALNY
Sec Filings
- 3/26/26 - Form SCHEDULE
- 3/6/26 - Form 4
- 3/6/26 - Form 4
- ALNY's page on the SEC website